(1) Patient groups. (2) Pharmacies. (3) Manufacturers of drugs. (4) Common or contract carriers and warehousemen. (5) Hospitals, physicians, and other health care providers. (6) State attorneys general. (7) Law enforcement officials, including local law enforcement officials. (8) Health benefit plans and entities that provide pharmacy benefit management services on behalf of a health benefit plan. (9) Wholesale drug distributors.
What is House Bill H.R. 4709?
This bill would require the Secretary of Health and Human Services to put together a report "assessing how patient access to medications could be
adversely impacted by Federal and State law enforcement
activities," and identify "how collaboration between [drug enforcement] agencies and
stakeholders can benefit patients and prevent diversion and
abuse of controlled substances." The report will incorporate feedback from a workgroup comprised of
Impact
The bill impacts shareholders in drug manufacturing companies, U.S. prescription drug abuse, and the Controlled Substances Act.
Cost of House Bill H.R. 4709
A CBO cost is currently unavailable.
More Information
AKA
Ensuring Patient Access and Effective Drug Enforcement Act of 2014
Official Title
To improve enforcement efforts related to prescription drug diversion and abuse, and for other purposes.
bill Progress
- Not enactedThe President has not signed this bill
- The senate has not voted
- senate Committees
Committee on Health, Education, Labor, and Pensions - The house Passed July 29th, 2014Passed by Voice Vote
- house Committees
Committee on Energy and CommerceHealthCommittee on the JudiciaryCrime, Terrorism and Homeland SecurityIntroducedMay 21st, 2014
Log in or create an account to see how your Reps voted!